The Science Behind XIENCE

“We've done this over a few generations of XIENCE, and have really optimized the deliverability for this implant.”

 Jamey Jacobs, Divisional Vice President, Global Product development, Abbott 

The XIENCE mechanism of action combines best in class deliverability with XIENCE Sierra, a proven design, and a unique, durable fluoropolymer for thromboresistance and reduced inflammation. This is why it's the most implanted stent worldwide.

“A drug-eluting stent consists of three components ... a metallic platform, a polymer and a drug, all influencing acute and long-term results both in safety and in efficacy.” 

— Jean Fajadet, MD1 


Unique Design Behind XIENCE Safety Data

All components of the XIENCE drug-eluting stent are designed for safety as well as efficacy.

STENT DESIGN

  • Flexible stent and delivery system offer more conformability to vessel anatomy2 
  • Low metal-to-artery ratio reduces injury and/or inflammation3 
  • Thin struts are designed for rapid healing and reduced thrombogenicity4,5

COATING TECHNOLOGY

  • Fluorinated polymer is associated with thromboresistance6 and minimal inflammation7 
  • Faster endothelialization and more functional endothelium8-10
  • Coating offers durability, flexibility and elasticity11,12

DRUG

  • Everolimus, patented to reduce restenosis 
  • Elution rate matches restenosis cascade by optimal coating thickness
  • Cytostatic

In addition, XIENCE Sierra offers excellent deliverability and unsurpassed precision in placement.

 

Unique Design Behind XIENCE Safety Data

All components of the XIENCE stent are designed for safety as well as efficacy.

STENT DESIGN

  • Flexible stent and delivery system offer more conformability to vessel anatomy2 
  • Low metal-to-artery ratio reduces injury and/or inflammation3 
  • Thin struts are designed for rapid healing and reduced thrombogenicity4,5

COATING TECHNOLOGY

  • Fluorinated polymer is associated with thromboresistance6 and minimal inflammation7 
  • Faster endothelialization and more functional endothelium8-10
  • Coating offers durability, flexibility and elasticity11,12

DRUG

  • Everolimus, patented to reduce restenosis 
  • Elution rate matches restenosis cascade by optimal coating thickness
  • Cytostatic
Experts' Point of View: XIENCE's Fluoropolymer Benefits

“We used to think in the early days of drug-eluting stents ... that having to add the polymer to control the dose and elution kinetics of the drug was a necessary evil. But I think we're learning here, in terms of thromboresistance, that the [XIENCE] polymer can be a plus.”

Gregg Stone, MD

Play video

Just as the stent design is critical to patient outcomes, so is the polymer coating. Hear what physicians have to say about the XIENCE fluoropolymer and its thromboresistance.

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.


SIGN UP
Sign up

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.


‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. Fajadet J, et al. PLATINUM PLUS. TCT 2012.
  2. Colombo A, et al. JACC. 2002;40:1021-1033.
  3. Data on file at Abbott Vascular.
  4. Kolandaivelu K, et al. Circulation. 2011;123;1400-1409.
  5. Kastrati A, et al. Circulation. 2001;103;2816-2821.
  6. Panchalingam V, et al. ASAIO J. 1993;39:M305-M309.
  7. Paton DM, et al. U.S. Patent 5,356,668.
  8. Ding NI, et al. J Interv Cardiol. 2009;22:S18-S27.
  9. Ao PY, et al. Eur J Vasc Endovasc Surg. 2000;20:241-249.
  10. Joner M, et al. JACC. 2008;52:333-342.
  11. Tu RH, et al. U.S. Patent 4,816,339.
  12. Lo ES. U.S. Patent 3,178,399. 

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer

Xiencestent.com is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit the International section of this website?